Biography
Bryce D. Carmine retired as an executive vice president of Eli Lilly and Co. and president of Lilly Bio-Medicines in 2011. This followed a career in global senior leadership positions beginning in 1975 in New Zealand and extending to South Korea, Australia, Japan, and ultimately the U.S. These U.S. leadership roles spanned both global commercial responsibilities and late phase product development across the breadth of the Lilly portfolio. During this time, he also actively represented the company on several pharma industry associations on health and policy matters.
Post retirement, Carmine has been involved with two Australian based Biotechs— Kazia Therapeutics, as an independent director, and HaemaLogiX, as both chairman and CEO since the company’s inception. During and post the pandemic he has been a resident in Sydney, Australia.
Carmine earned a B.S. in biochemistry from Massey University in New Zealand.